子宫内接受西地那非治疗的儿童2岁时神经发育结局:STRIDER随机对照试验
STRIDER superiority双盲随机对照试验在20个英国胎儿医学中心纳入135例严重早发型胎儿生长受限孕妇,随机接受西地那非25 mg每日三次或安慰剂至分娩或32周。西地那非未延长妊娠或改善围产结局,也未改善FGR存活儿的神经发育;作者结论为不应为此适应症处方西地那非。
要点
- 西地那非未改善FGR孕妇的至分娩时间或围产结局。
- 2岁时神经发育或血压与安慰剂组无差异。
- 作者结论为不应为此适应症处方西地那非。
核心结论
- 西地那非治疗未延长妊娠或改善围产结局,也未改善FGR存活儿的神经发育。
- 因此,不应为此适应症处方西地那非。
研究设计与样本
- 优越性、双盲随机对照试验。
- 设置:20个英国胎儿医学中心。
- 人群:孕22+0至29+6周、腹围低于第10百分位且脐动脉舒张末期血流缺失的胎儿生长受限妊娠。
- 方法:西地那非25 mg每日三次或安慰剂至分娩或孕32周。
- 主要结局:无脑瘫或神经感觉损害且Bayley-III综合评分>85的存活。
主要发现
- 2014年11月至2016年7月共随机135例孕妇(西地那非组70例,安慰剂组65例)。
- 75例婴儿(55.5%)存活出院,61例符合随访条件(西地那非组32例,安慰剂组29例)。
- 1例婴儿死亡(安慰剂组),3例母亲拒绝,10例母亲无法联系。
- 西地那非组2岁时头围中位差异49.2 cm(IQR 46.4-50.3)vs 安慰剂组47.2 cm(95% CI 44.7-48.9 cm)。
- 西地那非治疗后神经发育或血压无差异。
关键数值与推荐
- 主要结局为无脑瘫或神经感觉损害且Bayley-III综合评分>85的存活。
- 西地那非剂量25 mg每日三次,至分娩或孕32周。
临床怎么用
- 作者结论为不应为此适应症处方西地那非。
局限性
- 75例婴儿(55.5%)存活出院,61例符合随访条件。
- 1例婴儿死亡(安慰剂组),3例母亲拒绝,10例母亲无法联系。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Severe early-onset fetal growth restriction (FGR) causes stillbirth, neonatal death and neurodevelopmental impairment. Poor maternal spiral artery remodelling maintains vasoactive responsiveness but is susceptible to treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, which may improve perinatal outcomes. DESIGN: Superiority, double-blind randomised controlled trial. SETTING: A total of 20 UK fetal medicine units. POPULATION: Pregnancies affected by FGR, defined as an abdominal circumference below the tenth centile with absent end-diastolic flow in the umbilical artery between 22+0 and 29+6 weeks of gestation. METHODS: Treatment with sildenafil (25 mg three times/day) or placebo until delivery or 32 weeks of gestation. MAIN OUTCOME MEASURES: All infants alive at hospital discharge were assessed for cardiovascular function and cognitive, speech/language and neuromotor impairment at 2 years of age. The primary outcome was survival without cerebral palsy or neurosensory impairment, or a Bayley-III composite score of >85. RESULTS: In total, 135 women were randomised between November 2014 and July 2016 (70 to sildenafil and 65 to placebo). We previously published that there was no improvement in time to delivery or perinatal outcomes with sildenafil. In all, 75 babies (55.5%) were discharged alive, with 61 infants eligible for follow-up (32 sildenafil and 29 placebo). One infant died (placebo), three mothers declined and ten mothers were uncontactable. There was no difference in neurodevelopment or blood pressure following treatment with sildenafil. Infants who received sildenafil had a larger head circumference at 2 years of age (median difference 49.2 cm, IQR 46.4-50.3, vs 47.2 cm, 95% CI 44.7-48.9 cm). CONCLUSIONS: Sildenafil therapy did not prolong pregnancy or improve perinatal outcomes and did not improve infant neurodevelopment in FGR survivors. Therefore, sildenafil should not be prescribed for this condition.
引用
- Sharp A, Cornforth C, Jackson R, et al. Neurodevelopmental outcomes at 2 years in children who received sildenafil therapy in utero: The STRIDER randomised controlled trial. BJOG. 2024. PMID: 38923115. doi:10.1111/1471-0528.17888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。